| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 09/05/2002 | US20020123462 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 09/05/2002 | US20020123459 Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| 09/05/2002 | US20020123141 Recovering embryonic-like stem cells from a placenta; obtain placenta, drain cord blood, flush placenta with anticoagulant solution, recover cells |
| 09/05/2002 | US20020123099 Highly expressible genes |
| 09/05/2002 | US20020123093 Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia |
| 09/05/2002 | DE10111160A1 Neue Catecholat-ß-Laktamkonjugate, Verfahren zu ihrer Herstellung und ihre Anwendung New cathecolate ß-Laktamkonjugate, processes for their preparation and their use |
| 09/05/2002 | DE10106718A1 Hefestamm von Saccharomyces cerevisiae mit funktioneller Expression eines Glut-Transporters Yeast strain of Saccharomyces cerevisiae with functional expression of Glut-transporter |
| 09/04/2002 | EP1236800A2 Nucleic acids encoding interferon alpha 2, containing single nucleotide polymorphisms and methods of use thereof |
| 09/04/2002 | EP1236725A1 Novel 1,8-naphthyridin-2(1h)-one derivatives |
| 09/04/2002 | EP1236723A1 Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
| 09/04/2002 | EP1236720A1 Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors |
| 09/04/2002 | EP1236719A1 Novel heterocyclic compounds and salts thereof and medicinal use of the same |
| 09/04/2002 | EP1236475A2 Combination therapy for osteoporosis consisting of an estrogen agonist/antagonist and a growth hormone secretagogue |
| 09/04/2002 | EP1236468A1 Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders |
| 09/04/2002 | EP1236462A1 Multi-lamella based emulsion for stabilizing dermatologically useful ingredients and external preparation containing the same |
| 09/04/2002 | EP1235936A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 09/04/2002 | EP1235934A2 Screening method for candidate drugs |
| 09/04/2002 | EP1235933A2 Mammalian toxicological response markers |
| 09/04/2002 | EP1235860A2 G-protein coupled receptors |
| 09/04/2002 | EP1235846A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 09/04/2002 | EP1235835A1 Chromium-histidine complexes as nutrient supplements |
| 09/04/2002 | EP1235830A2 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS |
| 09/04/2002 | EP1235827A2 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 09/04/2002 | EP1235825A1 Novel benzoimidazole derivatives useful as antiproliferative agents |
| 09/04/2002 | EP1235824A1 Vitamin d analogues |
| 09/04/2002 | EP1235814A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS |
| 09/04/2002 | EP1235812A2 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 09/04/2002 | EP1235809A1 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use thereof as medicaments |
| 09/04/2002 | EP1235801A2 Solid pharmaceutical preparation |
| 09/04/2002 | EP1235799A1 Polymorphic form of atorvastatin calcium |
| 09/04/2002 | EP1235797A1 Aralkyl-1,2-diamines having calcimimetic activity and preparation mode |
| 09/04/2002 | EP1235787A1 $g(b)2-ADRENERGIC RECEPTOR AGONISTS |
| 09/04/2002 | EP1235785A2 Novel compounds to treat diabetes and associated conditions |
| 09/04/2002 | EP1235777A2 Vitamin d analogues |
| 09/04/2002 | EP1235618A2 Bioconjugation in vivo to pulmonary or blood components |
| 09/04/2002 | EP1235581A2 Use of ribose to prevent cramping and soreness in muscles |
| 09/04/2002 | EP1235578A2 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 09/04/2002 | EP1235488A1 Product and method for control of obesity |
| 09/04/2002 | EP1175390A4 Disodium salts, monohydrates, and ethanol solvates |
| 09/04/2002 | EP1091951B1 Novel polyoxypropylenepolyoxyethylene vitamin e and preparation thereof |
| 09/04/2002 | EP1037888B1 (e)-3-[1-n-butyl- 5-[2-(2-carboxyphenyl)methoxy- 4-chlorophenyl]-1h- pyrazol-4-yl]-2- [(5- methoxy-2,3- dihydrobenzofuran-6-yl)methyl]- prop-2-enoic acid monoargininyl salt |
| 09/04/2002 | EP0977583B1 Compositions comprising conjugates of stable, active, human ob protein with immunoglobulin fc chain and methods |
| 09/04/2002 | EP0832074B1 Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists |
| 09/04/2002 | EP0830348B1 Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists |
| 09/04/2002 | EP0809636B1 Substituted isoxazoles for the treatment of inflammation |
| 09/04/2002 | EP0760664B1 Use of pteridine derivatives as no-synthase inhibitors |
| 09/04/2002 | EP0738107B1 Inhibitors of fatty acid synthesis as antimicrobial agents |
| 09/04/2002 | EP0700397B1 New thiazolidindiones and drugs containing them |
| 09/04/2002 | CN1367816A Fat compositions |
| 09/04/2002 | CN1367793A Neuromedin B and somatostatin receptor agonists |
| 09/04/2002 | CN1367792A Somatostatin agonists |
| 09/04/2002 | CN1367787A Water soluble SDZ-RAD esters |
| 09/04/2002 | CN1367696A Method of enhancing insulin action |
| 09/04/2002 | CN1367695A Phthalazine derivatives for treating inflammatory diseases |
| 09/04/2002 | CN1367693A Pharmaceutical compositions containing poly(ADP-ribose) glycohydrolase inhibitors and method of using the same |
| 09/04/2002 | CN1367687A Calcilytic compounds |
| 09/04/2002 | CN1367169A Substituted 6,6-Hetero-dicycloderivative |
| 09/04/2002 | CN1367017A Application of transitional scorpion toxin BmK abT |
| 09/04/2002 | CN1367015A Nano supplemented ganoderma fungus preparation medicine and its preparation method |
| 09/04/2002 | CN1367001A Capsule for reducing blood-lipid and preventing thrombosis |
| 09/04/2002 | CN1366991A Application of plant extract for preparing medicine to cure bone absorption increment diseases |
| 09/04/2002 | CN1366957A Nano Bawei Shenqi preparation medicine and preparation method |
| 09/04/2002 | CN1366932A Nano Jinshuibao preparation medicine and preparation method |
| 09/04/2002 | CN1366906A Nano blood sugar-reducing preparation medicine and preparation method thereof |
| 09/04/2002 | CN1366905A Nano jueming blood-fat-reducing preparation medicine and preparation method thereof |
| 09/04/2002 | CN1366885A Bee product composition for curing diabetes and its preparation method |
| 09/04/2002 | CN1366883A Chitin lozenge and its preparation method |
| 09/04/2002 | CN1090189C Pyrazolopyrimidines type compound |
| 09/03/2002 | US6444829 (2s,4r)-4-mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carboxylic acid n'-isobutyl-n'-(4-methyl-benzenesulfonyl)-hydrazide, for example; inhibitors of metalloproteases, e.g. zinc proteases; vasodilators |
| 09/03/2002 | US6444827 From beta-methyl l-aspartate via chemical intermediate; efficiency; antidiabetic agents |
| 09/03/2002 | US6444811 Central nervous system disorders; cardiovascular disorders |
| 09/03/2002 | US6444800 Human gastric cancer antigen gene and gastric cancer antigen protein |
| 09/03/2002 | US6444709 Skin disorders; antiinflammatory agents; antiarthritic agents; cardiovascular disorders |
| 09/03/2002 | US6444708 Treatment using venlafaxine |
| 09/03/2002 | US6444701 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase |
| 09/03/2002 | US6444700 Nutrient mixture of vitamin c and e, beta-carotene, selenium and glyceride |
| 09/03/2002 | US6444696 1-aryl or heteroaryl substituted 5-amino-4 carbonylpyrazole derivatives; antiinflammatory agents |
| 09/03/2002 | US6444691 1,3-disubstituted ureas as ACAT inhibitors, and method of preparing thereof |
| 09/03/2002 | US6444688 Compounds and compositions with nitrogen-containing non-basic side chains |
| 09/03/2002 | US6444687 Eating disorders and diabetes |
| 09/03/2002 | US6444685 N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
| 09/03/2002 | US6444677 5-membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 09/03/2002 | US6444675 Promoting weight loss and treating eating disorders |
| 09/03/2002 | US6444669 8,8a-dihydroindeno[1,2-d]thiazole derivatives which carry in the 2-position a substituent having a sulfonamide structure or sulfone structure; processes for their preparation and their use as medicaments |
| 09/03/2002 | US6444657 2-(phosphonomethyl)pentanedioic acid; 2-(2-sulfanylethyl) pentanedioic acid; epithelial tissue scarring, collagen vascular disease, fibroproliferation, connective tissue disorder, respiratory distress syndrome; tgf regulator |
| 09/03/2002 | US6444646 Use of angiotensin II type 2 receptor agonists in tissue repair |
| 09/03/2002 | US6444227 Radiation or enzyme crosslinked gelatin |
| 09/03/2002 | US6444226 Purification and stabilization of peptide and protein pharmaceutical agents |
| 09/03/2002 | CA2065799C Thiazolidinedione derivatives, their production and their use |
| 09/01/2002 | CA2373578A1 .beta.3, agonists and uses thereof |
| 08/29/2002 | WO2002066978A2 Detection of compounds that modulate inflammatory responses |
| 08/29/2002 | WO2002066649A2 ANTI-INTERFERON-α ANTIBODIES |
| 08/29/2002 | WO2002066646A2 Neurotransmission-associated proteins |
| 08/29/2002 | WO2002066635A1 Transgenic animal having drug metabolism enzyme gene and utilization thereof |
| 08/29/2002 | WO2002066516A2 Antibodies that bind both bcma and taci |
| 08/29/2002 | WO2002066512A1 Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| 08/29/2002 | WO2002066509A2 Treatment involving dkk-1 or antagonists thereof |
| 08/29/2002 | WO2002066505A2 Gmg-3, gmg-4, and gmg-6 polynucleotides and polypeptides and uses thereof |
| 08/29/2002 | WO2002066484A1 Isoxazoline derivatives as anti-depressants |
| 08/29/2002 | WO2002066480A2 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |